studies

Extensive stage SCLC (Es-SCLC) - 1st Line (L1), durvalumab plus tremelimumab plus SoC vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCASPIAN (DT ; all population), 2019 0.82 [0.68; 0.99] 0.82[0.68; 0.99]CASPIAN (DT ; all population), 201910%537NAnot evaluable progression or deaths (PFS)detailed resultsCASPIAN (DT ; all population), 2019 0.84 [0.70; 1.01] 0.84[0.70; 1.01]CASPIAN (DT ; all population), 201910%537NAnot evaluable objective responses (ORR)detailed resultsCASPIAN (DT ; all population), 2019 1.02 [0.72; 1.44] 1.02[0.72; 1.44]CASPIAN (DT ; all population), 201910%537NAnot evaluable AE (any grade)detailed resultsCASPIAN (DT ; all population), 2019 4.09 [0.86; 19.46] 4.09[0.86; 19.46]CASPIAN (DT ; all population), 201910%532NAnot evaluable AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.05 [0.74; 1.49] 1.05[0.74; 1.49]CASPIAN (DT ; all population), 201910%532NAnot evaluable AE leading to death (grade 5)detailed resultsCASPIAN (DT ; all population), 2019 1.89 [0.98; 3.64] 1.89[0.98; 3.64]CASPIAN (DT ; all population), 201910%532NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsCASPIAN (DT ; all population), 2019 2.63 [1.59; 4.36] 2.63[1.59; 4.36]CASPIAN (DT ; all population), 201910%532NAnot evaluable STRAE (any grade)detailed resultsCASPIAN (DT ; all population), 2019 1.45 [0.96; 2.20] 1.45[0.96; 2.20]CASPIAN (DT ; all population), 201910%532NAnot evaluable STRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.28 [0.83; 1.98] 1.28[0.83; 1.98]CASPIAN (DT ; all population), 201910%532NAnot evaluable TRAE (any grade)detailed resultsCASPIAN (DT ; all population), 2019 1.04 [0.59; 1.84] 1.04[0.59; 1.84]CASPIAN (DT ; all population), 201910%532NAnot evaluable TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.15 [0.81; 1.61] 1.15[0.81; 1.61]CASPIAN (DT ; all population), 201910%532NAnot evaluable TRAE leading to death (grade 5)detailed resultsCASPIAN (DT ; all population), 2019 6.24 [1.38; 28.14] 6.24[1.38; 28.14]CASPIAN (DT ; all population), 201910%532NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCASPIAN (DT ; all population), 2019 3.75 [1.97; 7.16] 3.75[1.97; 7.16]CASPIAN (DT ; all population), 201910%532NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 7.10 [2.44; 20.63] 7.10[2.44; 20.63]CASPIAN (DT ; all population), 201910%532NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 6.06 [0.30; 121.51] 6.06[0.30; 121.51]CASPIAN (DT ; all population), 201910%532NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.25 [0.01; 5.54] 0.25[0.01; 5.54]CASPIAN (DT ; all population), 201910%532NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.68 [0.40; 1.15] 0.68[0.40; 1.15]CASPIAN (DT ; all population), 201910%532NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.51 [0.25; 9.08] 1.51[0.25; 9.08]CASPIAN (DT ; all population), 201910%532NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.01 [0.18; 22.28] 2.01[0.18; 22.28]CASPIAN (DT ; all population), 201910%532NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 4.02 [0.18; 89.63] 4.02[0.18; 89.63]CASPIAN (DT ; all population), 201910%532NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 3.57 [0.73; 17.33] 3.57[0.73; 17.33]CASPIAN (DT ; all population), 201910%532NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.66 [0.11; 4.01] 0.66[0.11; 4.01]CASPIAN (DT ; all population), 201910%532NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.69 [0.32; 1.48] 0.69[0.32; 1.48]CASPIAN (DT ; all population), 201910%532NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 4.02 [0.18; 89.63] 4.02[0.18; 89.63]CASPIAN (DT ; all population), 201910%532NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 5.08 [0.59; 43.75] 5.08[0.59; 43.75]CASPIAN (DT ; all population), 201910%532NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.08 [0.51; 2.28] 1.08[0.51; 2.28]CASPIAN (DT ; all population), 201910%532NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.60 [0.14; 2.52] 0.60[0.14; 2.52]CASPIAN (DT ; all population), 201910%532NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.92 [0.64; 1.32] 0.92[0.64; 1.32]CASPIAN (DT ; all population), 201910%532NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 3.02 [0.31; 29.25] 3.02[0.31; 29.25]CASPIAN (DT ; all population), 201910%532NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.02; 50.59] 1.00[0.02; 50.59]CASPIAN (DT ; all population), 201910%532NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 6.06 [0.30; 121.51] 6.06[0.30; 121.51]CASPIAN (DT ; all population), 201910%532NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.91 [0.50; 1.67] 0.91[0.50; 1.67]CASPIAN (DT ; all population), 201910%532NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.02; 50.59] 1.00[0.02; 50.59]CASPIAN (DT ; all population), 201910%532NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.14; 7.15] 1.00[0.14; 7.15]CASPIAN (DT ; all population), 201910%532NAnot evaluable Alopecia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.50 [0.04; 5.53] 0.50[0.04; 5.53]CASPIAN (DT ; all population), 201910%532NAnot evaluable Anaemia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.67 [0.41; 1.07] 0.67[0.41; 1.07]CASPIAN (DT ; all population), 201910%532NAnot evaluable Asthenia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.68 [0.40; 7.10] 1.68[0.40; 7.10]CASPIAN (DT ; all population), 201910%532NAnot evaluable Back pain AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.50 [0.02; 14.94] 0.50[0.02; 14.94]CASPIAN (DT ; all population), 201910%532NAnot evaluable Constipation AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Cough AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.53 [0.49; 13.15] 2.53[0.49; 13.15]CASPIAN (DT ; all population), 201910%532NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.37 [0.61; 9.26] 2.37[0.61; 9.26]CASPIAN (DT ; all population), 201910%532NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.51 [0.42; 5.42] 1.51[0.42; 5.42]CASPIAN (DT ; all population), 201910%532NAnot evaluable Fatigue AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.20; 5.00] 1.00[0.20; 5.00]CASPIAN (DT ; all population), 201910%532NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.81 [0.39; 1.69] 0.81[0.39; 1.69]CASPIAN (DT ; all population), 201910%532NAnot evaluable Headache AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Hypertension AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 7.16 [0.88; 58.62] 7.16[0.88; 58.62]CASPIAN (DT ; all population), 201910%532NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 2.00 [0.07; 59.99] 2.00[0.07; 59.99]CASPIAN (DT ; all population), 201910%532NAnot evaluable Increased Lipase Level AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.51 [0.42; 5.42] 1.51[0.42; 5.42]CASPIAN (DT ; all population), 201910%532NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.92 [0.43; 2.01] 0.92[0.43; 2.01]CASPIAN (DT ; all population), 201910%532NAnot evaluable Nausea AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.29; 3.50] 1.00[0.29; 3.50]CASPIAN (DT ; all population), 201910%532NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.95 [0.66; 1.37] 0.95[0.66; 1.37]CASPIAN (DT ; all population), 201910%532NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.39; 2.56] 1.00[0.39; 2.56]CASPIAN (DT ; all population), 201910%532NAnot evaluable Pruritus AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.00 [0.02; 50.59] 1.00[0.02; 50.59]CASPIAN (DT ; all population), 201910%532NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.50 [0.02; 14.94] 0.50[0.02; 14.94]CASPIAN (DT ; all population), 201910%532NAnot evaluable Rash AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 6.06 [0.30; 121.51] 6.06[0.30; 121.51]CASPIAN (DT ; all population), 201910%532NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 0.96 [0.53; 1.72] 0.96[0.53; 1.72]CASPIAN (DT ; all population), 201910%532NAnot evaluable Vomiting AE (grade 3-4)detailed resultsCASPIAN (DT ; all population), 2019 1.34 [0.30; 6.04] 1.34[0.30; 6.04]CASPIAN (DT ; all population), 201910%532NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:33 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 162 - treatments: 861